TY - JOUR
T1 - Programmed Cell Death Protein 1 Contributes to Oral Cancer Pain via Regulating Tumor Necrosis Factor Alpha in the Spinal Trigeminal Nucleus Caudalis
AU - Mao, Runyi
AU - Liu, Sufang
AU - Dolan, John C.
AU - Schmidt, Brian L.
AU - Tao, Feng
N1 - Publisher Copyright:
© 2025 Bentham Science Publishers.
PY - 2025
Y1 - 2025
N2 - Background: Oral cancer causes intense pain at the primary site, and such pain can impair oral functions. However, the underlying mechanisms for oral cancer pain are still not fully understood. In the present study, it is investigated whether programmed cell death protein 1 (PD-1) is involved in the development of oral cancer pain. Methods: RMP1-14, a specific anti-PD-1 antibody, was injected into spinal trigeminal nucleus caudalis (Sp5C) and measured pain behaviors using von Frey filaments and dolognawmeter. Western blotting and immunofluorescence staining were performed to analyze the expression of PD-1 and tumor necrosis factor alpha (TNFα) in the Sp5C. Results: It was observed that the PD-1 antibody significantly inhibited mechanical hypersensitivity and functional allodynia in our oral cancer pain mouse model. Moreover, we found that TNFα was highly upregulated in the Sp5C following the induction of oral cancer pain and that intra-Sp5C injection of the PD-1 antibody diminished the upregulation of TNFα. It was found that genetic deletion of TNFα or its receptor antagonism synergized the analgesic effect of PD-1 antibody on oral cancer pain. Conclusion: Our results suggest that PD-1 in the Sp5C contributes to oral cancer pain by altering TNFα signaling in the trigeminal nociceptive system, and PD-1 could be targeted to develop a novel approach for oral cancer pain management.
AB - Background: Oral cancer causes intense pain at the primary site, and such pain can impair oral functions. However, the underlying mechanisms for oral cancer pain are still not fully understood. In the present study, it is investigated whether programmed cell death protein 1 (PD-1) is involved in the development of oral cancer pain. Methods: RMP1-14, a specific anti-PD-1 antibody, was injected into spinal trigeminal nucleus caudalis (Sp5C) and measured pain behaviors using von Frey filaments and dolognawmeter. Western blotting and immunofluorescence staining were performed to analyze the expression of PD-1 and tumor necrosis factor alpha (TNFα) in the Sp5C. Results: It was observed that the PD-1 antibody significantly inhibited mechanical hypersensitivity and functional allodynia in our oral cancer pain mouse model. Moreover, we found that TNFα was highly upregulated in the Sp5C following the induction of oral cancer pain and that intra-Sp5C injection of the PD-1 antibody diminished the upregulation of TNFα. It was found that genetic deletion of TNFα or its receptor antagonism synergized the analgesic effect of PD-1 antibody on oral cancer pain. Conclusion: Our results suggest that PD-1 in the Sp5C contributes to oral cancer pain by altering TNFα signaling in the trigeminal nociceptive system, and PD-1 could be targeted to develop a novel approach for oral cancer pain management.
KW - Oral cancer pain
KW - functional allodynia
KW - hypersensitivity
KW - programmed cell death protein 1
KW - spinal trigeminal nucleus caudalis
KW - tumor necrosis factor-alpha
UR - http://www.scopus.com/inward/record.url?scp=105002011574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105002011574&partnerID=8YFLogxK
U2 - 10.2174/1570159X23666241209160039
DO - 10.2174/1570159X23666241209160039
M3 - Article
C2 - 39660489
AN - SCOPUS:105002011574
SN - 1570-159X
VL - 23
SP - 594
EP - 601
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 5
ER -